Indicated for use in cases involving suspected metastasis with PCa or suspected PCa recurrence due to elevated PSA level, Gozellix reportedly has a longer shelf life than other gallium-based PET imaging products.
The Food and Drug Administration (FDA) has approved Gozellix® (TLX007-CDx), a new preparation kit for the PSMA PET agent gallium-68 (68Ga) gozetotide.
After radiolabeling with 68Ga, Gozellix is indicated for PSMA PET imaging of men with suspected metastasis of prostate cancer (PCa), according to Telix Pharmaceuticals, the developer of Gozellix. The company said Gozellix is also approved for PSMA PET imaging in cases of suspected PCa recurrence based on elevated prostate-specific antigen (PSA) level.
For men with suspected metastasis or recurrence of prostate cancer, the FDA has approved the use of Gozellix, a preparation kit for the PSMA PET agent 68Ga gozetotide, which offers a longer shelf life (up to six hours) than other gallium-based PSMA PET products, according to Telix Pharmaceuticals, the developer of Gozellix. (Image courtesy of Adobe Stock.)
Telix Pharmaceuticals noted that key advantages with Gozellix include a longer shelf life (up to six hours) in comparison to other gallium-based PSMA PET products. An extended distribution radius may enable the use of Gozellix in PET scanning for areas not being served by other PSMA imaging providers, according to the company.
(Editor’s note: For additional content on prostate cancer imaging, click here.)
Emphasizing the scalable production capability with Gozellix, Telix Pharmaceuticals suggested the product facilitates flexibility with scheduling and efficiency of PSMA PET scanning, bolstering access to the imaging technology for patients with prostate cancer.
“Securing FDA approval for Gozellix is a major win for prostate cancer patients, who gain enhanced access to state-of-the-art 68Ga PSMA-PET imaging,” noted Kevin Richardson, the chief executive officer for Telix Precision Medicine. “With the launch of Gozellix, our team is excited to be bringing the new generation of prostate cancer scanning to more American men, delivered with the reliability, service and flexibility that customers have come to expect from Telix.”
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Large Medicare Study Shows Black Men Less Likely to Receive PET and MRI for Prostate Cancer Imaging
August 1st 2025An analysis of over 749,000 Medicare beneficiaries diagnosed with prostate cancer over a five-year period found that Black men were 13 percent less likely to receive PET imaging and 16 percent less likely to receive MRI in comparison to White men.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
August 1st 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Study Reveals Significant Prevalence of Abnormal PET/MRI and Dual-Energy CT Findings with Long Covid
August 1st 2025In a prospective study involving nearly 100 patients with Long Covid, 57 percent of patients had PET/MRI abnormalities and 90 percent of the cohort had abnormalities on dual-energy CT scans.